442.56 0.00 (0.00%)
After hours: 5:52PM EDT
|Bid||434.00 x 100|
|Ask||442.55 x 100|
|Day's Range||442.01 - 448.57|
|52 Week Range||325.35 - 543.55|
|PE Ratio (TTM)||44.40|
|Earnings Date||Nov 8, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||498.26|
Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.
Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy."
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
TARRYTOWN, N.Y. and PARIS, Oct. 16, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive results from a Phase 2 investigational study of dupilumab in adults with active moderate-to-severe eosinophilic esophagitis. The study showed that patients who received dupilumab weekly reported a significant improvement in the ability to swallow versus placebo. The results of this study were presented at the World Congress of Gastroenterology (WCOG) held in partnership with The American College of Gastroenterology Annual Scientific Meeting (ACG 2017) in Orlando, Florida.
Regeneron became a star with its treatment for a common eye disease, but treatments for dermatitis, arthritis, asthma and cancer could bring superstardom.
Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).
TARRYTOWN, N.Y. , Oct. 11, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2017 financial and operating results on Wednesday, ...
With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.
TARRYTOWN, N.Y. and CAMBRIDGE, Mass. , Oct. 11, 2017 /PRNewswire/ -- Understand AD: A Day in the Life Raises Awareness of Atopic Dermatitis by Sharing Real Stories from the AD Community, Driving Empathy ...
AnaptysBio soared Tuesday after its eczema drug appeared to outperform a potential blockbuster rival drug from Regeneron and Sanofi.
Gabelli & Co. We reiterate a Buy rating on Regeneron Pharmaceuticals with an estimated 2018 private market value of $554 a share. On Oct. 5, Regeneron (REGN) announced that the appeals court has removed the permanent injunction on Praluent. The injunction was issued in January to block sales of Praluent, after a federal jury ruled against Regeneron in patent litigation and declared two of Amgen’s (AMGN) patents linked to PCSK9 in March 2016 valid.
Amgen's patents covering LDL cholesterol-lowering drug Repatha are likely to be invalidated, an analyst says.
Regeneron Pharmaceuticals(REGN) and partner Sanofi, Inc. (SNY) receives a favorable ruling from the Court of Appeals for the Federal Circuit relating to Praluent.
NEW YORK, NY / ACCESSWIRE / October 6, 2017 / Shares of Amgen had a modest close in the red while Regeneron shares had a modest close in the green. A U.S. appeals court reversed a ban on a cholesterol-lowering ...
A U.S. federal appeals court said Regeneron Pharmaceuticals and partner Sanofi can continue selling their cholesterol drug, dealing a blow to rival Amgen, which had accused the companies of violating its ...
PARIS and TARRYTOWN, N.Y., Oct. 5, 2017 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Court of Appeals for the Federal Circuit has ordered a new trial and vacated the permanent injunction in the dispute concerning Amgen's asserted patent claims for antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). This ruling means that Sanofi and Regeneron will continue marketing, selling and manufacturing Praluent® (alirocumab) injection in the U.S.
Praluent continues to be available to patients in the U.S. TARRYTOWN, N.Y. and PARIS, Oct. 5, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Court of Appeals for the Federal Circuit has ordered a new trial and vacated the permanent injunction in the dispute concerning Amgen's asserted patent claims for antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). This ruling means that Sanofi and Regeneron will continue marketing, selling and manufacturing Praluent® (alirocumab) injection in the U.S.
Shares of Amgen (AMGN) are sliding this morning after a judge ruled that Regeneron Pharmaceuticals' (REGN) Praluent can stay on the market for the time being. The ruling was made in an ongoing patent battle between Amgen and Regeneron and its partner Sanofi (SNY). The Court is allowing for REGN's Praluent to stay on the market for the time being on the basis the that earlier proceeding in district court was conducted in error.
Ten analysts were covering Exelixis in October 2017. One analyst suggested a “strong buy,” and five analysts suggested a “buy” rating.
Key highlights this week include Amgen's (AMGN) agreement with AbbVie related to its biosimilar version of Humira and Endocyte's in-licensing deal which sent its shares soaring.
Endocyte (ECYT) acquired an exclusive worldwide license to develop and commercialize ABX GmbH's phase III-ready prostate cancer candidate 177Lu-PSMA-617.
Allergan (AGN) announced that the FDA has accepted the application for the label expansion of Avycaz to include a new indication and study data.
With biotech stocks on a tear, here we have picked three of the biggest biotech companies which look well poised for growth and can be added to one's portfolio